FDA Issues Early Communication About Ongoing Safety Review Of Weight Loss Drug Orlistat
Links shared publicly online about this topic.
- 1,434total visits
FDA Issues Early Communication About Ongoing Safety Review Of Weight Loss Drug Orlistat
The U.S. Food and Drug Administration announced that it is reviewing adverse event reports of liver injury in patients taking the weight loss drug orlistat, marketed as the prescription drug Xenic
View full resource at medicalnewstoday.com
Tags: Liver, Obesity Medication, Weight Loss, Drug, FDA, Xenical
Most Recently Shared on December 31, 1969 at 7:00 pm By:
FDA Issues Early Communication About Ongoing Safety Review Of Weight Loss Drug Orlistat: The U.S. Food and Drug .. http://bit.ly/i2t2n
Advertisement
